Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations
NCT06062823
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
35
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Interventions
DRUG:
Afatinib 40 MG
Sponsor
National University Hospital, Singapore